CGM + nutrition program bundles account for 46.1% of offering revenue in 2026, metabolic health & prediabetes holds 46.7% of user-goal revenue, and 1-3 month programs represent 51.8% of program-length revenue. Easier OTC sensor access expands trial demand, but evidence limits and repeat self-pay costs restrict renewal.